-
Nov 6, 2024 | 
medscape.com | Tania Jain |Gabriela Hobbs
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Tania Jain, MBBS: Hello, everyone. I'm Tania Jain. Welcome to episode six, the concluding episode of season 1 of the Medscape InDiscussion podcast series on myelofibrosis.
-
Oct 3, 2024 | 
medscape.com | Tania Jain |Jeanne M. Palmer
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Tania Jain, MBBS: Hi, everyone. I'm Tania Jain. Welcome back to the myelofibrosis podcast for Medscape InDiscussion. The topic for today is transplantation in myelofibrosis. I have a very special guest today, Dr Jeanne Palmer.
-
Aug 21, 2024 | 
wonkhe.com | Tania Jain |Mark Leach
Universities have come in for plenty of criticism for allegedly taking too much equity in spinout companies – which is then said to have a negative impact on growth, venture capital, and innovation. University incubators have struggled to deliver financial returns and spinout numbers commensurate with the rise in recent investment from strained university budgets.
-
Aug 21, 2024 | 
wonkhe.com | Tania Jain
firstname surname Email Organisation Job Title* Job Area Job Level By submitting you agree to our terms and conditions
-
Jul 3, 2024 | 
medscape.com | Tania Jain |Aaron Gerds
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Tania Jain, MBBS: Hello, everyone, and welcome to this myelofibrosis podcast series. The topic for today is clinical trials and investigational therapeutics in myeloproliferative neoplasms (MPNs).
-
May 15, 2024 | 
nature.com | Trent Wang |Nausheen Ahmed |Andy Chen |Narendranath Epperla |Bradley M. Haverkos |Nasheed M. Hossain | +10 more
AbstractCD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2–9).
-
May 10, 2023 | 
onclive.com | Tania Jain
Tania Jain, MBBS, director, Adult Chimeric Antigen Receptor T-cell Therapy Program for Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, assistant professor of oncology, Johns Hopkins Medicine, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.
-
Apr 6, 2023 | 
onclive.com | Tania Jain
Tania Jain, MBBS, director, Adult Chimeric Antigen Receptor T-cell Therapy Program for Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of haploidentical donors (HD) in myelofibrosis. At the 2023 Transplantation and Cellular Therapy Meetings, investigators presented blood and marrow transplant outcomes with haploidentical and unrelated donor types in myelofibrosis.
-
Mar 6, 2023 | 
onclive.com | Tania Jain
Tania Jain, MBBS, director, Adult Chimeric Antigen Receptor T-cell Therapy Program for Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, Assistant Professor of Oncology, Johns Hopkins Medicine, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant (allo-SCT).
-
Feb 27, 2023 | 
onclive.com | Tania Jain
Taina Jain, MBBS, director, Adult Chimeric Antigen Receptor T-cell Therapy Program for Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center, Assistant Professor of Oncology, Johns Hopkins Medicine, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors (HD) in myelofibrosis.
